Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Meningococcal vaccine Stories

2008-12-08 21:42:29

One-fifth of the standard dose of a commonly used meningitis vaccine may be as effective as using the full dose, researchers in Norway said. Researchers at the Norwegian Institute of Public Health and colleagues at Epicentre -- the research arm of Doctors Without Borders/Medecins Sans Frontieres -- and Mbarara University of Science and Technology in Uganda said the finding should allow scarce vaccine resources to be stretched further, especially during epidemics in Africa. In 2004, a...

2008-12-05 12:46:38

One fifth of the standard dose of a commonly used meningitis vaccine may be as effective as using the full dose. This new finding should allow scarce vaccine resources to be stretched further, especially during epidemics in Africa.In a study initiated by the Norwegian Institute of Public Health, together with Epicentre (the research arm of Doctors Without Borders/M©decins Sans Frontires), and Mbarara University of Science and Technology in Uganda, immune responses in patients receiving...

7a87d1045edeb5b20af31e89e72d4a891
2008-12-02 11:20:11

Researchers said on Tuesday, that giving just one-fifth the dose of a commonly used meningitis vaccine, may be as effective as using the full dose. The findings will allow medics to stretch scarce vaccine resources, especially places like Africa. Similar immune responses in patients given low and full doses of Sanofi-Aventis's vaccine Menomune was discovered during a clinical study in Uganda by Epicentre. Serum Bactericidal Activity (SBA) response with a fifth dose was comparable to full dose...

2008-11-12 12:00:31

Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, a French pharmaceutical group, has announced that it is the first international vaccine company to enter the Japanese pediatric vaccine market with ActHIB vaccine. Sanofi Pasteur's ActHIB vaccine (Haemophilus influenzae type b conjugate vaccine) is marketed in Japan by Daiichi-Sankyo Co and will be available starting December 19, 2008. Wayne Pisano, president and CEO of Sanofi Pasteur, said: "Sanofi Pasteur is proud to help...

2008-09-18 06:00:19

Reportlinker.com announces that a new market research report related to the Infectious diseases industry is available in its catalogue. World Human Vaccines Market http://www.reportlinker.com/p092575/World-Human-Vaccines-Market.html This report analyzes the worldwide markets for Human Vaccines in Millions of US$. The major product segments analyzed are Prophylactic Vaccines (Pediatric Prophylactic Vaccines, & Adult Prophylactic Vaccines), and Therapeutic Vaccines. The report...

2008-06-23 06:00:31

SWIFTWATER, Pa. and LYON, France, June 23 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Pentacel(R), Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine. Pentacel(R) vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive...

2008-05-06 09:01:22

New Phase III data for Menveo(R) (MenACWY-CRM) show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Menactra(R). Infection with any of these four vaccine-preventable serogroups can lead to bacterial meningitis, an infection of the membrane around the brain and spinal cord, or sepsis, a serious infection of the blood stream. Results of this first head-to-head trial of Menveo compared to...

2006-04-06 12:48:14

NEW YORK (Reuters Health) - Three more cases of Guillain-Barre syndrome (GBS), a neurological disorder involving temporary paralysis, have been reported in people given the Menactra vaccine to prevent meningitis. The additional cases bringing the total number reported to eight, according to an article in the Morbidity and Mortality Weekly Report, published by the Centers for Disease Control and Prevention. Still, when the eight cases of Menactra-related GBS were compared against the...

2006-02-10 10:15:00

NEW YORK (Reuters Health) - In adolescents, intimate kissing with multiple partners, attending college, and a history of preceding illness are independent risk factors for meningococcal disease, whereas religious observance and meningococcal vaccination are tied to reduced risks, new research shows. Meningococcal disease -- a bacterial infection of the fluid within the tissues surrounding the brain and spinal cord -- is largely a disease affecting children younger than 5 years, although in...

2005-09-30 19:14:15

By Lisa Richwine WASHINGTON (Reuters) - U.S. officials are investigating if a Sanofi-Aventis meningitis vaccine may have caused five cases of a rare neurological disorder that can paralyze its victims, the government announced on Friday. The patients -- all 17 or 18 years old -- developed Guillain-Barre Syndrome, or GBS, after receiving Sanofi's Menactra vaccine, which was approved for sale in January. All are recovering or have recovered, officials said. The cases under...